IDH mutations were also found in 10–20% of patients with acute myeloid leukemia (AML), with a low incidence in other cancers; the majority of these lesions involve arginine (R) residue mutations in IDH1 codon 132 (IDH1 R132) and residues 140 and 172 of IDH2 (IDH2 R140 and IDH2 R172) [31, 32]. Here, IDH2 is linked to cancer.